There are 2 schools of thought on AI. One is that machine learning has come of age, offering drug developers a chance to harness AI technology to guide research work, offering a much greater chance of success through Phase III. The other side says this is just the latest over-hyped fad that will inevitably fade into the background as large and small companies continue to rely on traditional methods for finding and advancing the next generation of drugs. We’ll assemble a panel of experts at the annual BIO 2019 confab in Philadelphia to evaluate both sides of that argument in a lively debate over the future of AI in R&D and where we’re headed over the next 5 years. You can’t afford to miss this conversation. Moderated by John Carroll.
For more information and to register, visit https://endpts.com/
Cost: General admission ticket: $150
Session ID: 549575